Metagenomi Begins Genetic Treatment Ipo Rollout (pending:mgx)
Metagenomi, Inc. (MGX) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1/A registration statement. Metagenomi, Inc. is backed by major pharma firms as strategic investors and partners and is well-capitalized but is operating in a high-risk research area characterized by a slow-moving U.S. FDA for genetic treatments. Emeryville, California-based Metagenomi Technologies was founded to create a "comprehensive genome editing toolbox" to help treat diseases through genetic alterations.
Genome Insight Inks $23M In Series B-2 Funding
SAN DIEGO, CA, Genome Insight, a precision healthcare solutions company, announced that it has closed a $23 million in a Series B-2 investment.
Artificial Intelligence In Genomics Market To Reach $6.22B By 2029 - Exclusive Report By Meticulous Research®
REDDING, Calif., Dec. 7, 2022 /PRNewswire/ -- According to a new market research report titled, 'Artificial Intelligence in Genomics Market by Offering (Software, Services), Functionality (Sequencing, Gene Editing), Application (Diagnostics, Precision Medicine, Drug Discovery and...
Myome Secures $23M In Series B Funding To Deliver Clinical Whole Genome Insights To Help Families Manage Risk For Inherited Diseases
The oversubscribed series B financing led by Healthcare Venture Partners, added SoftBank Corp. and Natera to existing investors– Sequoia Capital, Foresite Capital, Founders Fund, among others MENLO PARK, Calif., June 21, 2022 /PRNewswire/ -- MyOme, a clinical whole genome platform...
Verge Genomics Secures $98M In New Financing
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
2021 EDITION SPECIAL OFFER! Buy Now for only $119.95 plus a FREE update in January
2022
Learn More
or
Buy Now
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
African Genomics Startup 54gene Raises $25M To Expand Precision Medicine Capabilities – Techcrunch
Less than 3% of genetic material used in global pharmaceutical research is from Africa. The staggering gap is quite surprising because Africans and people of African descent are reported to be more genetically diverse than any other population. Since launching in 2019, African genomics startup 54gene has been at the forefront of bridging this divide […]
Genome Medical Announces Acquisition Of Genematters And Closing Of $60M Series C Financing
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
Genomatica Closes $118M Series C To Amplify The Scale And Impact Of Sustainable Materials
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
Ag Biotech Pioneer Fraley Joins Trace Genomics Board
REDWOOD CITY, Calif., April 15, 2021 /PRNewswire/ -- Trace Genomics announces the appointment of Dr. Robert (Robb) Fraley to its board of directors. Dr. Fraley, who served for nearly 40 years as chief technology officer at Monsanto and helped develop the first genetically modified seed,...
Vizgen Secures $37M Series B Financing To Advance Spatial Genomics Through Commercialization Of Merscope™ Platform
Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE™ Platform Funding will accelerate company growth and infrastructure expansion leading up to full commercial launch CAMBRIDGE, Mass., April 7, 2021-- Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures. Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund.